Skip to main content
Top
Published in: Cancer Chemotherapy and Pharmacology 1/2021

Open Access 01-01-2021 | Gastric Cancer | Correction

Correction to: Successful management of hyperammonemia with hemodialysis on day 2 during 5‑fluorouracil treatment in a patient with gastric cancer: a case report with 5‑fluorouracil metabolite analyses

Authors: Yoshinao Ozaki, Hirotaka Imamaki, Aki Ikeda, Mitsuaki Oura, Shunsaku Nakagawa, Taro Funakoshi, Shigeki Kataoka, Yoshitaka Nishikawa, Takahiro Horimatsu, Atsushi Yonezawa, Takeshi Matsubara, Motoko Yanagita, Manabu Muto, Norihiko Watanabe

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2021

Login to get access

Excerpt

The article “Successful management of hyperammonemia with hemodialysis on day 2 during 5-fluorouracil treatment in a patient with gastric cancer: a case report with 5-fluorouracil metabolite analyses”, written by Yoshinao Ozaki · Hirotaka Imamaki · Aki Ikeda · Mitsuaki Oura · Shunsaku Nakagawa · Taro Funakoshi · Shigeki Kataoka · Yoshitaka Nishikawa · Takahiro Horimatsu · Atsushi Yonezawa · Takeshi Matsubara ·Motoko Yanagita · Manabu Muto and Norihiko Watanabe, was originally published Online First without Open Access. After publication in volume 86, issue 5, page 693–699 the author decided to opt for Open Choice and to make the article an Open Access publication. Therefore, the copyright of the article has been changed to © The Author(s) 2020 and the article is forthwith distributed under the terms of the Creative Commons Attribution 4.0 International License (https://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. …
Metadata
Title
Correction to: Successful management of hyperammonemia with hemodialysis on day 2 during 5‑fluorouracil treatment in a patient with gastric cancer: a case report with 5‑fluorouracil metabolite analyses
Authors
Yoshinao Ozaki
Hirotaka Imamaki
Aki Ikeda
Mitsuaki Oura
Shunsaku Nakagawa
Taro Funakoshi
Shigeki Kataoka
Yoshitaka Nishikawa
Takahiro Horimatsu
Atsushi Yonezawa
Takeshi Matsubara
Motoko Yanagita
Manabu Muto
Norihiko Watanabe
Publication date
01-01-2021
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 1/2021
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-020-04193-y

Other articles of this Issue 1/2021

Cancer Chemotherapy and Pharmacology 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine